MX2007009142A - Formulaciones y regimen de dosificacion para modulares ppar-alfa. - Google Patents
Formulaciones y regimen de dosificacion para modulares ppar-alfa.Info
- Publication number
- MX2007009142A MX2007009142A MX2007009142A MX2007009142A MX2007009142A MX 2007009142 A MX2007009142 A MX 2007009142A MX 2007009142 A MX2007009142 A MX 2007009142A MX 2007009142 A MX2007009142 A MX 2007009142A MX 2007009142 A MX2007009142 A MX 2007009142A
- Authority
- MX
- Mexico
- Prior art keywords
- ppar
- methyl
- formulations
- dosing regimen
- alpha modulators
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 abstract 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 235000019260 propionic acid Nutrition 0.000 abstract 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 2
- 102000023984 PPAR alpha Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion proporciona regimenes de dosificacion para agonista PPAR-alfa y composiciones del mismo. otra modalidad de la presente invencion es una formulacion oral solida de Acido Propanoico, 2-[4-[3-[2,5-dihidro-1-[(4-metilfenil)metil]-5-oxo-1H- 1,2,4-triazol-3-il]propil]fenoxi]-2-metil- que comprende 75??g o menos de Acido Propanoico, 2-[4-[3-[2,5-dihidro-1-[(4-metilfenil) metil]-5-oxo-1H-1,2,4-triazol-3-il]propil]fenoxi]-2-metil- por unidad de dosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64790305P | 2005-01-28 | 2005-01-28 | |
| PCT/US2006/002606 WO2006083645A2 (en) | 2005-01-28 | 2006-01-25 | Formulations and dosing regimen for ppar-alpha modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007009142A true MX2007009142A (es) | 2007-11-21 |
Family
ID=36616964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007009142A MX2007009142A (es) | 2005-01-28 | 2006-01-25 | Formulaciones y regimen de dosificacion para modulares ppar-alfa. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080207716A1 (es) |
| EP (1) | EP1850845A2 (es) |
| JP (1) | JP2008528603A (es) |
| CN (1) | CN101106988A (es) |
| AR (1) | AR052888A1 (es) |
| BR (1) | BRPI0606805A2 (es) |
| CA (1) | CA2595770A1 (es) |
| DO (1) | DOP2006000018A (es) |
| MX (1) | MX2007009142A (es) |
| PE (1) | PE20061041A1 (es) |
| TW (1) | TW200640453A (es) |
| WO (1) | WO2006083645A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2688187C (en) | 2007-05-07 | 2016-10-11 | Merck & Co., Inc. | Method of treament using fused aromatic compounds having anti-diabetic activity |
| JP2013538215A (ja) | 2010-08-31 | 2013-10-10 | エスエヌユー アールアンドディービー ファウンデーション | ＰＰＡＲδアゴニストの胎児再プログラミング用途 |
| WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| DK2935228T3 (en) | 2012-12-20 | 2017-10-30 | Inception 2 Inc | TRIAZOLONE COMPOUNDS AND APPLICATIONS THEREOF |
| SG11201601066VA (en) | 2013-09-06 | 2016-03-30 | Inception 2 Inc | Triazolone compounds and uses thereof |
| WO2017044551A1 (en) * | 2015-09-11 | 2017-03-16 | Mitobridge, Inc. | Ppar-alpha agonists for treating mitochondrial diseases |
| CN118873522A (zh) | 2016-04-22 | 2024-11-01 | 无锡杰西医药股份有限公司 | 异硫氰酸酯类化合物的应用 |
| JP6976577B2 (ja) * | 2016-07-20 | 2021-12-08 | 国立大学法人東北大学 | ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA82048C2 (uk) * | 2000-11-10 | 2008-03-11 | Эли Лилли Энд Компани | Агоністи альфа-рецепторів, активованих проліфератором пероксисом |
| SE0101981D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
| DE60209824T2 (de) * | 2001-12-21 | 2006-10-19 | Smithkline Beecham Corp. | Dosierschema für ppar-gamma-aktivatoren |
-
2006
- 2006-01-24 PE PE2006000107A patent/PE20061041A1/es not_active Application Discontinuation
- 2006-01-24 AR ARP060100266A patent/AR052888A1/es unknown
- 2006-01-24 TW TW095102645A patent/TW200640453A/zh unknown
- 2006-01-24 DO DO2006000018A patent/DOP2006000018A/es unknown
- 2006-01-25 BR BRPI0606805-7A patent/BRPI0606805A2/pt not_active IP Right Cessation
- 2006-01-25 MX MX2007009142A patent/MX2007009142A/es not_active Application Discontinuation
- 2006-01-25 JP JP2007553198A patent/JP2008528603A/ja not_active Withdrawn
- 2006-01-25 EP EP06719460A patent/EP1850845A2/en not_active Withdrawn
- 2006-01-25 CN CNA2006800031037A patent/CN101106988A/zh active Pending
- 2006-01-25 US US11/814,487 patent/US20080207716A1/en not_active Abandoned
- 2006-01-25 WO PCT/US2006/002606 patent/WO2006083645A2/en not_active Ceased
- 2006-01-25 CA CA002595770A patent/CA2595770A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006083645A2 (en) | 2006-08-10 |
| EP1850845A2 (en) | 2007-11-07 |
| JP2008528603A (ja) | 2008-07-31 |
| DOP2006000018A (es) | 2006-07-15 |
| BRPI0606805A2 (pt) | 2010-02-09 |
| AR052888A1 (es) | 2007-04-11 |
| US20080207716A1 (en) | 2008-08-28 |
| PE20061041A1 (es) | 2006-10-12 |
| WO2006083645A3 (en) | 2006-12-28 |
| CN101106988A (zh) | 2008-01-16 |
| TW200640453A (en) | 2006-12-01 |
| CA2595770A1 (en) | 2006-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200702198A1 (ru) | Фармацевтические составы | |
| AR052153A1 (es) | Composiciones y metodos para la estabilizacion de ingredientes farmaceuticos activos | |
| CY1110260T1 (el) | Στερεες φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν εναν αγωνιστη υποδοχεα s1p και μια αλκοολη σακχαρων | |
| MA30474B1 (fr) | Formulations de molecule peptide(s) -anticorps therapeutique lyophilisee. | |
| IL179718A0 (en) | Pharmaceutical composition containing irbesartan | |
| WO2006011159A3 (en) | Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability | |
| PL1663194T3 (pl) | Zastosowanie SAHA do leczenia międzybłoniaka | |
| ZA200807597B (en) | Stable oral pharmaceutical composition containing thyroid hormone receptor agonists | |
| IL173742A0 (en) | Compositions for delivering 5-ht agonists across the oral mucosa | |
| MA30672B1 (fr) | Utilisation de derives de l'azabicyclo hexane | |
| MX2007009142A (es) | Formulaciones y regimen de dosificacion para modulares ppar-alfa. | |
| NO20043367L (no) | Oralt farmasoytisk preparat | |
| EA200900267A1 (ru) | КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ И СТЕРОИДОВ | |
| BR0215148A (pt) | Composições farmacêuticas de agonista parcial 5ht4 | |
| MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
| DK1185253T3 (da) | Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac | |
| EP2473051A4 (en) | NEW COMPOSITIONS AND METHODS OF PREPARING 5-AMINO OR SUBSTITUTED AMINO-1,2,3-TRIAZOLES AND TRIAZOOL OROTATE FORMULATIONS | |
| AU2003230189A1 (en) | Oral controlled release pharmaceutical composition containing metaxalone as active agent | |
| IL168836A (en) | Pyrimidine-sulfamides and their use as endothelin receptor antagonist | |
| Kottathil et al. | Compatibility of dual rinse 1-hydroxyethane-1, 1-diphosphonic acid with sodium hypochlorite solutions containing proprietary additives | |
| BRPI0403461A (pt) | composições estabilizadas contendo um agente ativo lábil ao oxigênio | |
| Larsen et al. | A laboratory study evaluating the release of hydroxyl ions from various calcium hydroxide products in narrow root canal‐like tubes | |
| MA30600B1 (fr) | Formulation medicamenteuse aqueuse d'acide 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl]benzoique. | |
| EA201000701A1 (ru) | 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465 | |
| AR062486A1 (es) | Formulaciones nuevas para la liberacion controlada de principios activos agroquimicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |